Synthesis, radiolabelling and biological characterization of (D)-7-iodo- N-(1-phosphonoethyl)-5-aminomethylquinoxaline-2,3-dione, a glycine-binding site antagonist of NMDA receptors

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 1, 2000, Pages 75-78

  Ametamey, Simon M ^a   Kokic, Marco ^a   Carrey Rémy, Nathalie ^a   Bläuenstein, Peter ^a   Willmann, Martine ^a   Bischoff, Serge ^b   Schmutz, Markus ^b   Schubiger, Pius A ^a   Auberson, Yves P ^b  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antagonists; Anticonvulsant; Labelling; Neurologically active compounds

Indexed keywords

2,3 QUINOXALINEDIONE DERIVATIVE; 7 IODO N (1 PHOSPHONOETHYL) 5 AMINOMETHYLQUINOXALINE 2,3 DIONE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN DISEASE; CONVULSION; DRUG DISTRIBUTION; DRUG LABELING; DRUG MECHANISM; DRUG SYNTHESIS; FEMALE; ISOTOPE LABELING; MOUSE; NONHUMAN;

ANIMALS; ANTICONVULSANTS; BINDING SITES; FEMALE; GLYCINE; INHIBITORY CONCENTRATION 50; IODINE RADIOISOTOPES; KIDNEY; MICE; MICE, INBRED BALB C; PHOSPHONIC ACIDS; QUINOXALINES; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTORS, N-METHYL-D-ASPARTATE; SUBSTRATE SPECIFICITY; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 0034598310     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00576-4     Document Type: Article

References (19)

1. Monyer H., Burnashev N., Laurie D.J., Sakmann B., Seeburg P. Neuron. 12:1994;529.
2. Garthwaite, J. In The NMDA Receptor; Collingridge, G. L.; Watkins, J. C., Eds.; Oxford University Press: Oxford, 1994; 2nd ed., pp. 428-456.
3. Olney J.W., Wozniak D.F., Farber N.B. Rest. Neurol. Neurosci. 13:1998;75.
4. Rothman S.M., Olney J.W. Trends Neurosci. 10:1987;299.
5. Choi D.W., Rothman S.M. Annual Rev. Neurosci. 13:1990;171.
6. Meldrum, B. S. Neurology 1994, 44 (Suppl. 8), S14.
7. Bruyn R.P.M., Stoof J.C. J. Neurol. Sci. 95:1990;29.
8. Auberson Y.P., Acklin P., Bischoff S., Moretti R., Ofner S., Schmutz M., Veenstra S.J. Bioorg. Med. Chem. Lett. 9:1999;249.
9. Schmutz M., Portet C., Jeker A., Klebs K., Vassout A., Allgeier H., Heckendorn R., Fagg G.E., Olpe H.R., van Riezen H. Naunyn-Schmiedeberg's Arch. Pharmacol. 342:1990;61.
10. Acklin P., Allgeier H., Auberson Y.P., Biollaz M., Bischoff S., Ofner S., Veenstra S.J. Bioorg. Med. Chem. Lett. 8:1998;493.
11. Auberson Y.P., Bischoff S., Moretti R., Schmutz M., Veenstra S.J. Bioorg. Med. Chem. Lett. 8:1998;65.
12. Baron B.M., Siegel B.W., Harrison B.L., Gross R.S., Hawes C., Towers P.J. Pharmacol. Exp. Ther. 279:1996;62.
13. Honoré T., Lauridsen J., Krogsgaard-Larsen P. J. Neurochem. 38:1982;173.
14. Simon J.R., Contrera J.F., Kuhar M.J. J. Neurochem. 26:1976;141.
15. Sills M., Fagg G., Angst C., Brundish D., Hurt S., Wilusz E., Williams M. Eur, J. Pharmacol. 192:1991;19.
16. Ransom R., Stec N. J. Neurochem. 51:1988;830.
17. Takagi K., Hayama N., Okamoto A. Chemistry Letters. 73:1978;191.
18. Ali, H.; Van Lier J. E. Synthesis 1995, 423.
19. Thorell J.O., Stone-Elander S., Ingvar M., Eriksson L. J. Labelled Comp. Radiopharm. 36:1994;251.